Current technologies for producing influenza vaccines in fertilized chicken eggs or by using cell culture-based manufacturing are characterized by:

• Low yields
• Overall lack of production capacity 
• Long lead time between identification of new virus strains and the manufacture of the bulk quantities needed for flu epidemic or pandemic
• Impracticality of egg-based production for avian H5N1 vaccine because of high virulence to chickens and eggs

The iBioLaunch™ platform was developed in response to these concerns and is capable of:

• Rapid & Efficient Production—transient nature of the gene expression technology and short growing cycle of non-genetically-modified plants create time-efficient production capabilities.
• High Production Capacity & Scalability—non-transgenic plants can be easily scaled-up in contained growth facilities to provide large amounts of biomass and expressed protein in a short period of time. 
• Increased Safety—plants are not infected with pathogens hazardous to humans or animals and the system eliminates the use of live infectious agents or tissues and materials of animal origin.
• Low Cost—facilities and source material provide economical product manufacturing capabilities.
• Flexibility—capable of rapid modification to produce enhanced vaccines in response to emerging or mutating virus strains